Diabetic nephropathy is defined as a microvascular complication of the kidneys induced by diabetes mellitus and is characterized by albuminuria and progressive loss of kidney function. However, neither albuminuria nor glomerular filtration rate decline are diabetic nephropathyspecific markers, thus the diagnosis of diabetic nephropathy greatly depends on assumptions. Several factors should be taken into account when urinary albumin levels are assessed before establishing the diagnosis of diabetic nephropathy, while newer more specific markers for diabetic nephropathy are urgently needed.
INTRODUCTION
Diabetic nephropathy (DN) is defined as the microvascular complication of the kidneys induced by diabetes mellitus and is characterized by albuminuria -ered as one of the microvascular complications of 1, 2 DN is vitrually the leading cause of end-stage kid- [3] [4] [5] The prevalence of DN varies enormously between continents, countries and even [5] [6] [7] [8] [9] However, the diagnosis of DN is an exclusion diagnosis depending on the presence of at least micro-on patients with type 1 DM, where the oncet is more or less obvious, and not on patients with type 2 DM, where the oncet is less pronounced and diagnosis According to Mogensen et al there are 5 stages in the course of DN (Figure1):
Stage 1, the stage at diagnosis, is characterized by hyperfiltration-increased estimated glomerular filtration rate (eGFR) and hypertrophy (increased can be present, aggravated during physical exercise, but these changes are at least partly reversible by Stage 2, the silent stage, develops over many years, without signs of clinical disease but still with characteristic morphologic lesions on biopsy specimens (glomerular basement membrane thickening, well controlled, albumin excretion is normal; however, By contrast, poor diabetes control leads to increased A number of patients continue in stage 2 throughout Stage 3, the incipient diabetic nephropathy stage, is characterized by abnormally elevated urinary albumin excretion, within the microalbuminuria range Stage 4, the classic overt diabetic nephropathy stage g/24h) and persistent high blood pressure and, if left untreated, eGFR declines at a mean rate of 1 2 treatment reduces this eGFR decline rate by about
Stage 5 is end-stage renal failure with uremia due

RETINOPATHY AND DN
Diabetic nephropathy (DN) and diabetic retinopathy (DR) are considered as interrelated diabetic vascular complications since kidneys and retina share similar 1,2 In clinical practice, the diagnosis of DR is used as the "non-interventional kidney biopsy" a history of DM for at least 5 years and albuminuria, with or without decrease in eGFR, the co-existence of DR strengthens the clinical suspicion that the patient exclude DN, since DR is present in approximately proven DN, while non-diabetic kidney disease was 13 Diabetic retinopathy incidence varies between studies and this probably relates to the duration of the 14 Diabetic retinopathy seems to better correlate with DN in type 1 DM and much less in type 14 15 In the same study, microalbuminuria was identified as a risk factor for DR in type 1 DM patients but not for type 2, whereas overt nephropathy 15 Manaviat et al 16 showed that the prevalence of any stage of DR in the -ably reflecting the more advanced diabetic vascular Therefore, DR does not serve as a reliable indica-
MICROALBUMINURIA AS A MARKER OF ENDOTHELIAL DYSFUNCTION AND DN
Microalbuminuria (MA) can occur both in patients with DM without present or future DN as well as in patients without DM but with other types of progressive chronic kidney disease and therefore it does not serve as a specific marker for the presence 17 Mogensen et al showed that MA predicts early mortality in type 2 DM and identified MA a cardiovascular and renal risk factor in both diabetic and 18 Parving reported an increase in urinary albumin excretion rate in poorly controlled hypertensive patients 19 and Bigazzi et al showed that MA predicts cardiovascular events and renal 20 Endothelial dysfunction has been suggested as underlying the renal and/or cardiovascular organ damage observed 21 The Steno hypothesis proposed that an increased permeability of the vascular endothelium constitutes a high risk for microangiopathy and a tendency to large 22 This systemic transvascular leakiness for albumin is associated with clinical atherosclerotic 23 The initiating event of the -dynamic stress or due to dyslipidemia and, according to the 'response-to-injury' hypothesis, the increased transendothelial permeability to macromolecules is 24 Therefore, while MA better predicts the development of DN in type 1 DM, MA in type 2 DM serves both as a marker of DN and of generalized endothelial not progress to the stage of overt proteinuria and these are probably the patients with hypertensive glomerulosclerosis compared to the patients that will progress obvious that in a type 2 DM patient with MA, with or without eGFR decline, but with also a long-standing history of hypertension and general atherosclerotic vascular findings, even if both of the criteria for DN Longer follow-up of both eGFR and proteinuria may
REGRESSION OF MICROALBUMINURIA
Microalbuminuria may not always be a marker of an irreversible renal injury, but most likely of acute renal stress and, due to this, not rarely regression of -sion rate to overt proteinuria has been reported to albumin through a retrieval transcytotic pathway or as amino acids after being degraded in the lysosomes (degradation pathway amount of this degraded albumin is re-excreted in the urine as fractions of the initial molecule, not measured in urine samples when First, the amount of albumin filtered through the glomerulus depends on the serum concentration of on dietary protein intake, the rate of synthesis and the amount secreted from the liver cells, the distribution Habitual dietary protein intake varies significantly in humans depending upon age, gender and lean 28 Although there are reports suggesting that in healthy individuals dietary protein overload may not increase protein renal clearance, 29, 30 animal models showed that 31, 32 In humans also it was shown that consumption of excessive amounts of dietary protein promotes chronic renal disease through increased glomerular pressure and hyperfiltration 33 and might be harmful in patients 34 Therefore, dietary differences in the amount of protein consumption may result in differences in GFR and albumin clearance and the amount On the other hand, hypoalbuminemia is a multifactorial process that results from a decrease in albumin synthesis as well as an increase in breakdown, leakage to the extravascular space and decreased 35 Patients with obvious malnutrition, malabsorption syndrome (protein-losing enteropathy) or hepatic dysfunction and a chronic inflammatory state may have lower albumin serum levels due to Therefore, for the same degree of glomeruli damage, these patients are expected to have lower urine albumin levels due to the lower amount of plasma Second, for more than 30 years filtered albumin has been known to be reabsorbed by the proximal 36 30mg/day, amount of albumin found in final urine, this represents only the intact albumin that can be measured -tered albumin is reabsorbed mainly by the proximal tubule and to a lesser extent by downstream parts of 37 Albumin reabsorbed by the PTCs can return to the circulation either as intact albumin through a retrieval transcytotic pathway or as amino acids after being degraded in the lysosomes (degradation 38, 39 An amount of this degraded albumin is re-excreted in the urine as fractions of the initial molecule, not measured in urine samples when they protein content of the final urine has been estimated to be as high as 2 to 4 g/day 40, 41 and the amount of filtered albumin has been estimated to be 50 times higher than previously assumed, suggesting that on a daily basis the normal kidney filters nephrotic levels of albumin, most of it retrieved by the proximal 42, 43 Furthermore, beyond the glomerulus, the proximal Normally, under euglycemic conditions approxithe low-affinity-high-capacity Na + -glucose cotransporter SGLT2, primarily in the early segments of the affinity-low-capacity SGLT1 in the late segments 44 Hyperglycemia enhances the amounts of glucose filtered by the glomeruli and thus increases glucose delivery to both SGLT2 and SGLT1 enhancing glucose reabsorption in the - 45 Proximal tubular cells appear unable to decrease glucose transport rates adequately to prevent excessive changes in intracellular glucose when exposed to high glucose concentrations 46 and this leads to the notable growth phenotype of early diabetic proximal tubule 47 In the setting of normal tubuloglomerular feedback, this increased glucose tubular absorption leads to a strong tubular control of glomerular filtration in the early diabetic kidney, further enhancing glomerular hyperfiltration 45, 47 Therapeutic agents, which have been developed to inhibit SGLT-2 or to effect dual inhibition of SGLT-2/ SGLT-1 and are currently used for diabetes control in type 2 DM and type 1 DM, respectively, are also 48, 49 SGLT2 inhibitors could potentially exert nephro-protection not only through improved glycemic control effects are the blood pressure-lowering effect, since these reduce sodium reabsorption in the proximal tubule, but also afferent arteriole vasoconstriction through the tubuloglomerular feedback which leads to attenuation of diabetes-associated hyperfiltration and tubular hypertrophy and reduction in albuminuria, independent of their effects on blood pressure 50, 51 SGLT2 inhibition and the associated afferent vasoconstriction leads to an acute, dose-dependent reduction 2 and in 52 Thus, the decrease in glomerular hyperfiltration following good diabetes control in general could in part explain the decrease in MA in clinical practice, while SGLT 2 inhibitors contribute to this through additional It is obvious that the anatomical and functional integrity of the proximal tubule is crucial for the final amount of albumin found in the urine and thus for the affect the PTCs, 53 but also such drugs as cisplatin, ifosfamide, tenofovir, sodium valproate and aminoglycoside antibiotics, may influence PTCs function 54 Angiotensin-converting enzyme inhibitors (ACEinh) and angiotensin II receptor antagonists (ARBs) are probably the most common classes of antihypertensive beneficial effects on cardiovascular risk factors and all-cause mortality, both categories have been shown in several studies also to have beneficial renal outcomes, including time to end-stage renal failure or doubling of creatinine, but also in preventing progression of micro-to macroalbuminuria or even remission of micro-to normoalbuminuria, 55-58 thus intervening in 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors, referred to as "statins", widely used in diabetics for lipids control and cardiovascular protection, [59] [60] [61] have been shown also to increase albumin endocytosis by glomerular epithelial cells (podocytes), suggesting another pathway of retrieving albumin that leaks through the glomerular 62-64 Conversely, statins have been shown to reduce albumin endocytosis by PTCs and 65, 66 Taking all the above into account, it could be postulated that the amount of albumin detected in a spot urine sample, which is the criterion in order to characterize a patient as having DN or not, is the net result of several parameters that are both patient related (degree of glomerular damage, proximal tubular integrity, serum albumin levels), but also health professionals related (use of therapeutic agents that influence glomerular filtration of albumin such as ACE-inh/ARBs or statins, or tubular processing of the filtered albumin like SGLT2 inhibitors, as well as the degree of hypertension, glycemic and lipids control detected, the degree of the actual diabetic glomerular damage may not be the same, therefore the diagnosis of DN should be individualized and carefully set after assessment of all possible parameters that may
MICROALBUMINURIA: IS IT THE BEST WE CAN DO FOR EARLY DETECTION OF DN?
It has already been more than two decades since the first announcements of MA being an early marker of DN and, until lately, it has been regarded as the gold standard for the diagnosis and a predictor of progression to end-stage kidney disease in both type 1 67 68
However, as already analyzed above, though MA is an accessible and affordable screening marker for daily clinical practice, its predictive strength is not -forts into identifying new markers that precede the microalbuminuria stage and are more predictive of effort, the development of new diagnostic methods and especially the omics and microRNAs technology has led to novel markers, mainly from the urine that A number of key biomarkers present in the urine that reflect the pathophysiologic processes taking place in the diabetic kidney along the nephron (glo-merulus/podocytes, tubules) and also reflect the different mechanisms (tubular damage, oxidative stress, inflammation and activation of the intrarenal renin-69-71 For example, podocytes injury and/or decrease in their number per glomerulus is an early finding in DN, even prior to proteinuria, and therefore podocyturia-and podocyte-specific markers in the urine, including nephrin or Wilm's tumor-1 protein, could serve as 72, 73 patients with microalbuminuria and macroalbumin- 74 Positive urinary Wilms' Tumor-1 (WT1) without proteinuria, while in nondiabetic control 73 Vascular endothelial growth factor A (VEGF-A), a podocyte-derived biomarker, could also be a sensitive early marker of DN, but also a disease progression higher in diabetics, even in the absence of albuminuria, compared to nondiabetic healthy controls, and 75 Other podocytes markers could also be found early in the urine of diabetic patients, but their specificity -buminuric diabetic patients; 76 however, podocalyxin 77 of glomerular damage in patients with diabetes, even in the absence of albuminuria; 78 on the other hand, as with albumin it is not DN-specific, since other primary 79 Beyond podocytes (glomerular epithelium), glomerular endothelium has also been implicated in diabetic kidney disease pathophysiolgy and other patients excrete in urine significantly more glycosaminoglycans (GAGs), part of the endothelial glycocalyx, than controls 80 and such an increase has been reported in patients with all stages of albuminuria, while urinary GACs positively correlated with disease 81 Moreover, several other proteins have been reported -cellular structural matrix proteins (collagen type IV, fibronectin, metalloproteinases), transforming growth factor (TGF)beta the potent inducer of extracellular matrix proteins, markers of tubular damage like the apical membrane receptors megalin and cubilin, the transmembrane protein of the apical membrane of PTCs-kidney injury molecule 1 (KIM-1), but also neutrophil gelatinase-associated lipocalin (NGAL) that is produced in the distal nephron are examples of freely filtered by the glomerulus and reabsorbed by the these proteins increase even in the normoalbuminuric stage, 69,70 with some of them being detected up to 5 71
NON-DIABETIC NEPHROPATHY IN DIABETIC PATIENTS
When a diabetic patient develops clinical nephropathy with proteinuria, this could be due to progressive diabetic nephropathy, or another non--ported that another primary glomerulopathy may 82 83 84 of non-insulin who clinically were suspected not to have diabetic nephropathy and underwent a renal biopsy, Soni et al 85 reported that the most common non-diabetic renal -Furthermore, even if diabetic changes such as diffuse and nodular glomerulosclerosis are found in the kidney biopsy, it is important to determine whether these are secondary changes due to diabetic segmental glomerulosclerosis or idiopathic nodular glomerulosclerosis, in addition to diabetic nephropa- 86 Other nephropathies that share similar nodular histological features with diabetic nephropathy such as membranoproliferative glomerulonephritis, mono-clonal immunoglobulin deposition disease, amyloidosis, fibrillar glomerulopathy and idiopathic nodular glomerulosclerosis could be distinguished by detailed 86, 87 On the other hand, many diabetic patients with chronic kidney disease may not have significant proteinuria or albuminuria even in the late CKD stages and, therefore, classic diabetic nephropathy 88 patients with renal insufficiency and are more often older patients with a history of cardiovascular disease and usually treated with renin-angiotensin system 89, 90 Disease progression in this subgroup is slower, although histological analyses may show 89 The latter histological findings are more frequently seen in type 1 DM, whereas in type 2 DM a substantial proportion of patients have more advanced tubulo-interstitial and 91,92 On this basis, Dalla Vestra et al 93 have proposed a different classification system for renal lesions in diabetic kidney disease, comprising three major groups: I) normal or glomerular lesions and disproportionately more profound tubulo-interstitial lesions, advanced glomerular arteriolar hyalinosis and global glomerular sclerosis,
CONCLUSION
Microalbuminuria is currently used as the earliest limitations exist, since urinary albumin levels depend on several patient-related factors or health care profeseven in normoalbuminuric diabetic patients prior to the development of microalbuminuria could be Nevertheless, larger multicenter prospective studies are needed to confirm their clinical utility and costa marker of kidney damage in DM, but it must also be carefully assessed and monitored for a reasonable unexpectedly renal function deterioration occurs or overt proteinuria develops, nephrology consultation 
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